Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Earl Sallan, M.D.

Co-Author

This page shows the publications co-authored by Stephen Sallan and Richard Gelber.
Connection Strength

1.423
  1. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004 Jul 08; 351(2):145-53.
    View in: PubMed
    Score: 0.075
  2. Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity. J Clin Oncol. 2004 Jul 01; 22(13):2701-7.
    View in: PubMed
    Score: 0.075
  3. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol. 2002 Jan 01; 20(1):237-46.
    View in: PubMed
    Score: 0.063
  4. Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer. 2001 Jul 01; 92(1):15-22.
    View in: PubMed
    Score: 0.061
  5. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001 Mar 01; 97(5):1211-8.
    View in: PubMed
    Score: 0.059
  6. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001 Feb 15; 19(4):1040-6.
    View in: PubMed
    Score: 0.059
  7. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000 Dec; 14(12):2247-56.
    View in: PubMed
    Score: 0.058
  8. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000 Apr 15; 88(8):1964-9.
    View in: PubMed
    Score: 0.056
  9. Induction failure in acute lymphoblastic leukemia of childhood. Cancer. 1999 Mar 15; 85(6):1395-404.
    View in: PubMed
    Score: 0.052
  10. Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol. 1998 Aug; 16(8):2848-53.
    View in: PubMed
    Score: 0.050
  11. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer. 1997 Dec 15; 80(12):2285-95.
    View in: PubMed
    Score: 0.047
  12. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol. 1994 Apr; 12(4):740-7.
    View in: PubMed
    Score: 0.037
  13. Central nervous system treatment in childhood acute lymphoblastic leukemia. Long-term follow-up of patients diagnosed between 1973 and 1985. Cancer. 1993 Jul 01; 72(1):261-70.
    View in: PubMed
    Score: 0.035
  14. Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood. 1993 Mar 15; 81(6):1651-7.
    View in: PubMed
    Score: 0.034
  15. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer. 1992 Oct 15; 70(8):2208-13.
    View in: PubMed
    Score: 0.033
  16. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer. 1992 Jul 01; 70(1):201-6.
    View in: PubMed
    Score: 0.033
  17. The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol. 1992 May; 10(5):810-7.
    View in: PubMed
    Score: 0.032
  18. Health-related quality of life among children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Oct; 59(4):717-24.
    View in: PubMed
    Score: 0.032
  19. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood. 1991 Nov 15; 78(10):2514-9.
    View in: PubMed
    Score: 0.031
  20. Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols. Ann Oncol. 1991 Nov-Dec; 2(10):745-9.
    View in: PubMed
    Score: 0.031
  21. Dentofacial development in long-term survivors of acute lymphoblastic leukemia. A comparison of three treatment modalities. Cancer. 1990 Dec 15; 66(12):2645-52.
    View in: PubMed
    Score: 0.029
  22. Late effects of central nervous system treatment of acute lymphoblastic leukemia in childhood are sex-dependent. Dev Med Child Neurol. 1990 Mar; 32(3):238-48.
    View in: PubMed
    Score: 0.028
  23. More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus. 1990; 33:459-66.
    View in: PubMed
    Score: 0.027
  24. Prognostic implications of cytogenetic studies in an intensively treated group of children with acute lymphoblastic leukemia. Blood. 1989 Nov 01; 74(6):2130-5.
    View in: PubMed
    Score: 0.027
  25. Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol. 1989 Nov; 7(11):1594-601.
    View in: PubMed
    Score: 0.027
  26. Ophthalmic evaluation of survivors of acute lymphoblastic leukemia. Ophthalmology. 1988 Feb; 95(2):151-5.
    View in: PubMed
    Score: 0.024
  27. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007 Feb 01; 109(3):896-904.
    View in: PubMed
    Score: 0.022
  28. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986 Sep 11; 315(11):657-63.
    View in: PubMed
    Score: 0.022
  29. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1986; 14(4):211-5.
    View in: PubMed
    Score: 0.021
  30. Use of trimethoprim-sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatr Infect Dis. 1985 May-Jun; 4(3):265-9.
    View in: PubMed
    Score: 0.020
  31. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005 Apr 20; 23(12):2629-36.
    View in: PubMed
    Score: 0.020
  32. Echocardiographic (Echo) monitoring of myocardial injury during doxorubicin (DOX) therapy for childhood acute lymphoblastic leukemia (ALL). J Clin Oncol. 2004 Jul 15; 22(14_suppl):8505.
    View in: PubMed
    Score: 0.019
  33. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983 Nov; 43(11):5601-7.
    View in: PubMed
    Score: 0.018
  34. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003 Oct 01; 21(19):3616-22.
    View in: PubMed
    Score: 0.018
  35. Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol. 2003 Aug 01; 21(15):2953-60.
    View in: PubMed
    Score: 0.018
  36. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002 Dec 01; 20(23):4517-22.
    View in: PubMed
    Score: 0.017
  37. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol. 2002 Mar 15; 20(6):1677-82.
    View in: PubMed
    Score: 0.016
  38. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001 Jun 15; 19(12):3066-72.
    View in: PubMed
    Score: 0.015
  39. Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood. 1980 Mar; 55(3):395-402.
    View in: PubMed
    Score: 0.014
  40. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1999 Jan-Feb; 21(1):6-12.
    View in: PubMed
    Score: 0.013
  41. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Jan; 14(1):18-24.
    View in: PubMed
    Score: 0.010
  42. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995 06 29; 332(26):1738-43.
    View in: PubMed
    Score: 0.010
  43. Prognostic factors in medulloblastoma, including DNA ploidy. J Clin Oncol. 1993 Apr; 11(4):616-22.
    View in: PubMed
    Score: 0.009
  44. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991 Mar 21; 324(12):808-15.
    View in: PubMed
    Score: 0.007
  45. Outcome of pregnancy in survivors of Wilms' tumor. JAMA. 1987 Jan 09; 257(2):216-9.
    View in: PubMed
    Score: 0.006
  46. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res. 1985 Feb; 45(2):499-503.
    View in: PubMed
    Score: 0.005
  47. Second neoplasms after Wilms' tumor in childhood. J Natl Cancer Inst. 1983 Dec; 71(6):1205-9.
    View in: PubMed
    Score: 0.004
  48. Risk factors for thyroid abnormalities after neck irradiation for childhood cancer. Am J Med. 1983 Feb; 74(2):272-80.
    View in: PubMed
    Score: 0.004
  49. Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. J Clin Pharmacol. 1981 Aug-Sep; 21(S1):43S-50S.
    View in: PubMed
    Score: 0.004
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.